The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared with ipilimumab in the phase III, multicenter randomized KEYNOTE-006 trial (NCT01866319).
After two recent clinical trials provided long-awaited new information on the role of lymph node management in patients with melanoma, a panel was formed to update the 2012 ASCO-Society of Surgical Oncology (SSO) guidelines for sentinel lymph node (SLN) biopsy.
Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.
Although patients have benefited from the expansion of options, questions have arisen about how to select optimal treatment, such as whether to recommend lymph node dissection or immunotherapy compared with targeted therapy.
The 3 mg/kg dose is considered the “standard” dose of ipilimumab, however, there has continued to be debate in the field about the most appropriate dose of ipilimumab, and clinical trials have continued to investigate the 10 mg/kg dose.
The 2011 ASCO Annual Meeting Plenary Session ushered in a renaissance for melanoma therapy with the promise of targeted therapy. Results of the BRIM-3 trial marked the beginning of the end of cytotoxic chemotherapy for melanoma.
Treatment with binimetinib improved response rates and significantly prolonged progression-free survival compared with dacarbazine for patients with cutaneous melanoma with an NRAS mutation in the open-label, prospective phase III NEMO trial.
Updated results from CheckMate 067 show that with a minimum of 18 months follow-up the combination of nivolumab plus ipilimumab is still significantly superior compared with ipilimumab alone for patient with advanced melanoma.
Three KEYNOTE studies on pembrolizumab in metastatic melanoma provide insights into its long-term efficacy, its efficacy versus ipilimumab and its efficacy in combination with ipilimumab. What are the clues that hint at a cure for some patients with stage IV disease?
Are we “putting the cart before the horse” by adding dual immunotherapy agents in study designs when we haven't defined and identified predictive markers to select patient populations to test immunotherapy modalities?
The combination of nivolumab and ipilimumab significantly increased PFS in patients with advanced melanoma compared with ipilimumab alone, according to a randomized, double-blind, phase III trial. AEs were increased with the combination. The high cost of the drugs was also highlighted.
Performing a complete lymph node dissection after identifying micrometastases in the sentinel lymph nodes does not improve survival outcomes for patients with melanoma, according to results of a randomized, phase III, noninferiority trial conducted in Germany.